IOL Chemicals invests ₹500 Cr for growth in pharmaceuticals
pre-market1 source ↓written by the desknot a recommendation
- across three projects
- ₹500 crore
- could potentially drive
- 30% revenue growth
IOL Chemicals and Pharmaceuticals is investing ₹500 crore across three projects to enhance its Ibuprofen capacity, enter CDMO formulations, and develop a new specialty chemical facility. These initiatives aim to tap into the growing demand for backward-integrated APIs and strengthen customer relationships.
This strategic expansion could potentially drive 30% revenue growth, positioning the company favorably in the competitive pharmaceuticals sector.
Not investment advice. For informational purposes only.